Skip to content
Calculator

Peptide side effects and FDA safety risks

FDA keeps a list of bulk substances that it says may present significant safety risks when compounded, and 21 of the peptides sold online are on it. For each one, this page sets three things side by side: what FDA said, quoted from its page (current as of 04/22/2026); what human reports found, from the peptide's entry, where every line is sourced; and who should not use it. For most of these peptides the honest answer is that very few people have been studied, so "no side effects reported" usually means nobody looked closely, not that it is safe. This is not medical advice, and Grey Peptides sells nothing.

AOD-9604 side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.

What human reports found

From the company's six trials (2013 report) and FDA's compounding safety page.

  • Headache, the commonest adverse event in the trials, at similar rates on AOD-9604 and placebo
  • Mild or moderate euphoria in 5 of 23 people during intravenous AOD-9604 periods and none on placebo
  • Five cancers or tumours in the 12-week trial, all in AOD-9604 groups, judged unrelated by the investigator
  • Serious adverse events in 18 of 502 people (3.6%) in the 24-week trial, similar across groups
  • Possible immune reactions and impurities in compounded products; serious adverse events of unclear cause (FDA)

Who should not use it

  • Injection under the skin: never tested in a published trial
  • Cancer, or a history of it: five tumours occurred in AOD-9604 groups in one trial, and causality was not settled
  • Pregnancy, breastfeeding, children: no data
  • Expecting weight loss: its largest trial found none that was significant
  • Uncertain products: FDA notes impurity and characterisation problems in compounded peptides

1 more line with dose amounts is on the entry, beside its source.

BPC-157 side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.

What human reports found

FDA's May 11, 2026 evaluation of the five clinical studies found no serious adverse events reported, but the studies were short and small and safety monitoring in most was unclear. What the human reports and FDA record:

  • Headache and flatulence, the adverse events reported most often after enemas in healthy volunteers (2002 and 2003 meeting abstracts, as summarised by FDA)
  • In the ulcerative colitis enema study, three people on BPC-157 and two on placebo withdrew for adverse events, mainly worsening colitis (FDA's summary of a 2005 meeting abstract)
  • No treatment-related adverse events in the knee, bladder and intravenous reports, per a 2026 systematic review; the two-person intravenous pilot found no changes in heart, liver, kidney, thyroid or glucose markers
  • Possible immune reactions: FDA says injected or nasal BPC-157 may pose a significant immunogenicity risk, made worse by aggregation and peptide impurities (a concern, not an observed event)
  • Changes in clotting time (aPTT) and in ALT, glucose and triglycerides in repeat-dose intramuscular toxicity studies in rats and dogs, which FDA calls clinically relevant safety signals

Who should not use it

  • Pregnancy / breastfeeding (no safety data)
  • Active cancer (angiogenesis concerns)
  • Concurrent anticoagulant therapy
  • Known hypersensitivity to BPC-157
  • Children / adolescents (no pediatric data)

CJC-1295 side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.

What human reports found

From the two human studies and FDA's compounding safety page.

  • Serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction (FDA)
  • IGF-1 raised for up to 28 days after repeated doses, with a cumulative effect
  • Possible immune reactions from aggregation or impurities in compounded products (FDA)

Who should not use it

  • Heart disease or low blood pressure: FDA records increased heart rate and a vasodilatory reaction
  • Pituitary tumours or active cancer: it raises growth hormone and IGF-1 for weeks
  • Diabetes: growth hormone opposes insulin; no study measured glucose over time
  • Uncertain products: 'CJC-1295' may be the no-DAC peptide instead
  • Pregnancy, breastfeeding, children: no data

1 more line with dose amounts is on the entry, beside its source.

Dihexa side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

FDA has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration. FDA lacks important information regarding any safety issues raised by dihexa acetate, including whether it would cause harm if administered to humans.

What human reports found

There is no human safety data. The animal studies above did not report side effects in their abstracts.

  • No published study has given dihexa to people
  • In rats with a Huntington's-like toxin injury it did not prevent weight loss, learning deficits or motor dysfunction (2024)
  • Its proposed mechanism involves growth-factor signalling, and no study has examined its long-term safety, including cancer risk

Who should not use it

  • Cancer, or a history of it: its proposed growth-factor mechanism has never been tested for safety
  • Pregnancy, breastfeeding and childhood: no data
  • Research-chemical products: identity, dose, purity and sterility are unverified
  • Tested athletes: check the Sport (WADA) row in the table below

DSIP side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

What human reports found

The first human study reported that DSIP was well tolerated, with no psychological, physiological or biochemical side effects in six volunteers. The other abstracts give no adverse-event tables, and one found effects on the heart that matter more than the sleep results.

  • Six volunteers: no psychological, physiological or biochemical side effects observed
  • Anaesthetised patients: higher heart rate and lower heart-rate variability
  • Cats: less sleep and delayed REM sleep, the opposite of the intended effect
  • Injection-site irritation, the generic risk of any repeated injection
  • Unregulated product: contamination, the wrong peptide or the wrong amount in the vial

Who should not use it

  • Heart rhythm conditions: DSIP raised heart rate and lowered heart-rate variability in patients
  • Before surgery or sedation: it lightened anaesthesia in the one study that tested it
  • Pregnancy and breastfeeding: no data on this page
  • Under 18: no data on this page
  • Competitive athletes: check the sport row of the legal table before use
  • Anyone treating insomnia: the controlled trials were mixed, and approved treatments exist

Epithalon side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

What human reports found

No trial of synthetic epithalon in our evidence set reports an adverse-event table, so there is no human side-effect profile to quote. What the abstracts say about safety comes from animals, and the practical risks come from how research peptides are made and sold.

  • Mice given microgram doses for months to a lifetime: no toxic effects reported
  • Mice: no change in food intake or body weight across a lifetime of injections
  • People: no published adverse-event data for the synthetic peptide
  • Injection-site irritation, the generic risk of any repeated subcutaneous injection
  • Unregulated product: contamination, the wrong peptide or the wrong amount in the vial

Who should not use it

  • Current or past cancer: telomere lengthening was seen in breast-cancer cell lines, through the ALT pathway
  • Pregnancy and breastfeeding: there are no data of any kind
  • Under 18: no data, and no reason to expose growing tissue to an untested peptide
  • Taking melatonin or sleep medication: pineal and melatonin effects are reported in animals, and combinations are unstudied
  • Competitive athletes: check the sport row of the legal table before using any unapproved peptide
  • Anyone relying on the telomere claim: it rests on cell cultures, not on measurements in people

GHK-Cu side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.

What human reports found

The human abstracts report outcomes rather than adverse-event tables, so most of what is known comes from a single animal study and from the absence of human data.

  • Post-laser trial (13 patients): no objective benefit and no faster fading of redness; the abstract does not report adverse events either way
  • Venous-ulcer trial (86 patients): the 0.4% cream healed ulcers no better than an inert placebo
  • Guinea-pig wounds (1995): slower skin reorganisation and delayed fibroblast activation with GHK-Cu
  • Cultured fibroblasts in the same study: less cell reproduction, more collagen expression at 10⁻⁷ M
  • Injected GHK-Cu: no study in our evidence set tested it alone in people, so there is no human safety record; one uncontrolled study gave 1,000 people scalp injections of a growth-factor mixture that included it (Kapoor 2018, listed under References)

Who should not use it

  • Injection: US pharmacies cannot compound GHK-Cu for injection. FDA's 503A category list (Updated May 14, 2026; re-read October 27, 2026) dates the withdrawal of the nominations, and GHK-Cu's removal from Category 1, to April 22, 2026; only the non-injectable nomination was restored
  • Copper-handling disorders such as Wilson disease: GHK-Cu delivers copper, and no study has included people who cannot clear it. A reasoned caution, not a tested one
  • Active or past cancer: reviews by its discoverer credit GHK with stimulating blood-vessel growth and with anti-cancer activity, and neither has been tested in people with cancer
  • Open wounds: the evidence points both ways, with faster healing in rabbits, slower reorganisation in guinea pigs and no benefit over placebo in human leg ulcers
  • Pregnancy and breastfeeding: no data

GHRP-2 side effects

Approved abroad · FDA put it in category 2, substances it says raise significant safety risks.

What FDA said

Compounded drugs containing GHRP-2 for injectable and nasal administration may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. GHRP-2 also contains an unnatural amino acid, which adds to the complexity of peptide characterization. FDA is aware of reports of serious adverse advents in patients who received GHRP-2, including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis, though causality has not been established.

What human reports found

From the studies above; the Japanese diagnostic has its own label, which we have not read.

  • Increased hunger and food intake (35.9% more at a meal in one study)
  • ACTH and cortisol release, strong enough to serve as an adrenal test
  • Desensitisation of the growth hormone response with some chronic dosing patterns
  • No serious effects on major organ systems in animal safety pharmacology

Who should not use it

  • Adrenal or pituitary disease, where its ACTH and cortisol effects change test results
  • Competitive sport (see the Legal table below)
  • Pregnancy, breastfeeding and children outside a supervised study: no safety data
  • Any use outside a supervised diagnostic test or trial

GHRP-6 side effects

Research only · FDA put it in category 2, substances it says raise significant safety risks.

What FDA said

Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.

What human reports found

These come from the single-dose studies above. None was designed to find side effects, so the list is short because the evidence is thin, not because GHRP-6 has been shown to be safe.

  • Rises in ACTH and cortisol after single doses in healthy men, and a far larger ACTH response in Addison's disease on replacement
  • Changes in sleep: more stage 2 sleep, no change in deep sleep, after four overnight doses
  • Unexplained spikes in blood levels during elimination in four of nine volunteers, after large intravenous doses
  • Appetite: often described by users and plausible for a ghrelin-receptor agonist, but not measured in any study on this page

Who should not use it

  • Adrenal disease or cortisol excess: GHRP-6 raises ACTH and cortisol, and the response is altered in both Addison's disease and cortisol excess
  • Pituitary or hypothalamic damage: expect little or no growth hormone response
  • Thyroid disease: both underactive and overactive thyroid changed the hormonal response
  • Pregnancy, breastfeeding and childhood: no safety data outside single diagnostic doses
  • Research-chemical products: identity, dose and sterility are unverified
  • Tested athletes: check the Sport (WADA) row in the table below

Ipamorelin side effects

Research only · FDA put it in category 2, substances it says raise significant safety risks.

What FDA said

Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.

What human reports found

Published human safety data come from the 1999 dosing study and the 2014 phase 2 trial (the larger 320-patient trial, NCT01280344, posted no results); FDA's 2023 Category 2 notice adds its own reading of the literature.

  • Adverse events in 87.5% of patients on ipamorelin and 94.8% on placebo after bowel surgery, with no difference the authors attributed to the drug
  • FDA cites a published report of serious adverse events, including death, when ipamorelin was given intravenously to improve gastric motility
  • FDA also cites possible immune reactions from aggregation or peptide-related impurities in compounded products
  • A slightly smaller growth hormone response after 15 days of use in rats

Who should not use it

  • Any use outside a trial: FDA placed it in 503B Category 2 as a significant compounding safety risk
  • Pituitary tumours or other pituitary disease: it acts on the growth hormone axis, and no study tested its safety there
  • Diabetes: in rat pancreas tissue it raised insulin secretion, and growth hormone secretagogues as a class affect glucose; no human study measured this
  • Competitive sport: see the WADA row below; urine tests detect its metabolites after the parent peptide is gone
  • Pregnancy, breastfeeding, children: no data

Kisspeptin-10 side effects

In trials · FDA put it in category 2, substances it says raise significant safety risks.

What FDA said

Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.

What human reports found

From the small studies above.

  • No serious adverse events reported in these short physiology studies
  • Hormonal effects on LH, FSH and sex steroids are the intended action
  • Long-term safety unknown

Who should not use it

  • No approved use or dose
  • Not for use outside research
  • In FDA's Category 2 for compounding (significant safety concerns)

KPV side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.

What human reports found

No human safety data exist. These are the only safety-relevant findings in the studies above.

  • No published study has given KPV to people, so no human side effects have been recorded
  • Nanoparticle carriers were non-toxic to intestinal cells in culture (2017)
  • KPV breaks down under acid, alkali and oxidising stress, mainly into lysyl-proline diketopiperazine (2015)
  • In cells engineered to express MC1R it raised calcium, so effects through that receptor cannot be ruled out

Who should not use it

  • Pregnancy, breastfeeding and childhood: no data of any kind
  • Inflammatory bowel disease: the animal results are promising, but no human trial exists to replace proven treatment
  • Cancer: in mice KPV prevented colitis-associated tumours; nothing is known about established cancers in people
  • Research-chemical products: identity, dose, purity and sterility are unverified
  • Tested athletes: check the Sport (WADA) row in the table below

LL-37 side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing cathelicidin LL-37 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans. Nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues.

What human reports found

The wound trials reported LL-37 as safe and well tolerated on the skin, and the oral COVID-19 trial saw no severe adverse events. None of that tells us what injecting it does, and the laboratory findings add risks the trials were not designed to detect.

  • Topical use in leg ulcers: no local or systemic safety concerns in either trial
  • Oral recombinant LL-37: no severe adverse events during hospital stay and follow-up
  • Injected LL-37: no safety data in any carded study
  • Inflammation: LL-37 triggered inflammatory signals in human brain immune cells in culture
  • Unregulated product: contamination, the wrong peptide or the wrong amount in the vial

Who should not use it

  • Current or past cancer, especially breast cancer: LL-37 promoted migration and metastasis in breast cancer models
  • Rosacea or inflammatory skin disease: abnormally processed cathelicidin drives rosacea inflammation
  • Inflammatory conditions: it triggered inflammatory signalling in human glial cells and in skin
  • Pregnancy and breastfeeding: no data on this page
  • Competitive athletes: check the sport row of the legal table before use
  • Anyone expecting the wound-trial results from injections: those trials applied it to the wound

Melanotan II side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.

What human reports found

These come from the small trials, the forum study and published case reports. A case report shows that something happened, not how often it happens.

  • Spontaneous erections lasting one to five hours after doses, with yawning and stretching
  • Reduced appetite, reported more often than on placebo
  • Changes in existing moles and new atypical moles; four case reports of melanoma emerging from existing moles during or soon after melanotan use, counted by 2017
  • Priapism after an overdose (a 2013 letter)
  • Renal infarction attributed to melanotan II, after earlier reports of rhabdomyolysis and kidney failure

Who should not use it

  • Atypical moles or a history of melanoma: case reports link melanotan to changing moles and melanoma, though conclusive evidence is lacking
  • An erection lasting more than four hours is a medical emergency (priapism) and needs same-day care
  • Kidney disease or clotting disorders: a renal infarction and earlier kidney-failure reports raise a concern no study has measured
  • Sunbed use: forum users paired it with sunbeds, adding UV exposure to a pigment stimulant
  • Shared needles and unlabelled products: the forum study flagged infection and contamination, and tested vials held up to 5.9% unknown impurities
  • Pregnancy and breastfeeding: no data

2 more lines with dose amounts are on the entry, beside their source.

MK-677 side effects

Research only · FDA put it in category 2, substances it says raise significant safety risks.

What FDA said

Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients. The agency is aware of a randomized, placebo-controlled trial assessing ibutamoren mesylate for the treatment of patients recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”

What human reports found

These come from the trials and case reports above, which followed thousands of person-months of dosing.

  • Increased appetite, strongest in the first months of the year-long trial in older adults
  • Mild, transient swelling of the lower legs and muscle pain
  • Higher fasting glucose, impaired glucose tolerance and lower insulin sensitivity in older and obese adults
  • Weight and limb-fat gain alongside the lean-mass gain
  • A congestive heart failure signal that stopped a hip-fracture trial early (2011)
  • Raised liver enzymes in a case report (2025) and in a case taken with a SARM (2022)

Who should not use it

  • Heart failure or risk of it: a trial in older patients was stopped over heart failure, and FDA cites that risk
  • Diabetes or prediabetes: it raises fasting glucose and lowers insulin sensitivity
  • Frail older adults recovering from injury: the trials found little functional gain and an unfavourable safety profile
  • Active cancer: it raises IGF-1 into the young-adult range, and no trial studied people with cancer
  • Children, outside a registered trial: FDA found it hidden in children's growth products
  • Tested athletes: check the Sport (WADA) row in the table below

MOTS-c side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans.

What human reports found

We found no human adverse-event data for injected MOTS-c, because none of the studies in our evidence set gave it to people. The safety statements that exist come from mice, and the practical risks come from buying an unregulated research product.

  • Mice: no systemic toxicity reported in the ovarian cancer study
  • People: no published data on side effects of injected MOTS-c
  • Injection-site irritation, the generic risk of repeated subcutaneous injection
  • Low blood sugar: a theoretical risk given its insulin-sensitising action in mice
  • Unregulated product: contamination, the wrong peptide or the wrong amount in the vial

Who should not use it

  • Diabetes, or glucose-lowering drugs such as insulin or sulfonylureas: combined effects on blood sugar are unstudied
  • Pregnancy and breastfeeding: the only data come from diabetic pregnant mice
  • Under 18: no data
  • Cancer: one ovarian cancer study suggests an anti-tumour effect, but no study has tested safety in people with cancer
  • Competitive athletes: check the sport row of the legal table before use
  • Anyone hoping to skip exercise: in people, exercise raises MOTS-c; injecting it has not been shown to replace training

PEG-MGF side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing Mechano Growth Factor Pegylated (PEG-MGF) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration. FDA lacks important information regarding any safety issues raised by PEG-MGF, including whether it would cause harm if administered to humans.

What human reports found

No human side-effect report is recorded on the entry.

Selank side effects

Approved abroad · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans.

What human reports found

The clinical abstracts report benefits more than harms, and what they say about tolerability comes mainly from comparisons with benzodiazepines.

  • No adverse-event rates are given in the clinical abstracts on this page
  • Anti-fatigue and stimulant-like effects reported alongside the anti-anxiety effect (2008, 2014)
  • Added to phenazepam, fewer of the benzodiazepine's side effects, during treatment and after withdrawal
  • In rats, a course of selank without stress nudged anxiety measures toward worse, less than diazepam did
  • Long-term safety, tolerance and dependence: studied in no paper in our evidence set

Who should not use it

  • Benzodiazepines, alcohol or other sedatives: selank acts on GABA signalling, and interactions have been studied only in rats, where it added to diazepam's effect under stress
  • Opioids: selank slows the breakdown of the body's own opioid peptides, and its interaction with opioid drugs in people is unstudied. A reasoned caution, not a tested one
  • Autoimmune or inflammatory conditions: selank shifted cytokine balance in patients' blood, with effects nobody has followed up
  • Products sold as supplements: a 2021 review found selank sold that way in the US, where the contents and strength of such products are not independently verified
  • Pregnancy, breastfeeding and under-18s: no data

Semax side effects

Approved abroad · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

What human reports found

The clinical abstracts on this page report outcomes, not adverse-event tables, so there is no systematic side-effect profile to quote. What the evidence does raise are two pharmacological signals from animals, plus the risks of unregulated supply.

  • Amplified amphetamine effects in mice: more dopamine release and hyperactivity
  • Anticoagulant activity in animals, flagged in FDA's 2026 review
  • No adverse-event tables in the Russian clinical abstracts carded here
  • Nasal irritation, the generic risk of repeated intranasal dosing
  • Unregulated product: contamination, the wrong peptide or the wrong amount in the bottle

Who should not use it

  • Stimulants, including ADHD medication: semax dramatically enhanced amphetamine's effects in mice
  • Anticoagulants or bleeding disorders: FDA's review flagged anticoagulant activity in animals
  • Pregnancy and breastfeeding: no data on this page
  • Under 18: no data on this page
  • Competitive athletes: check the sport row of the legal table before use
  • Stroke or eye disease: the human studies are small and mostly uncontrolled, and no substitute for standard care

TB-500 side effects

Research only · FDA listed it among nominated substances it says may present significant safety risks. Under HHS's October 2026 interim policy, a licensed 503A pharmacy compound it on a prescription, under conditions; FDA's safety concerns below still stand.

What FDA said

Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.

What human reports found

No controlled study has given TB-500 to people, so its side effects in humans are unknown; the one three-patient report, which gave it with four other drugs, recorded no adverse events.

  • The animal studies of TB-500 examined healing, not safety
  • Products sold as TB500 and TB1000 did not consistently contain what their descriptions said

Who should not use it

  • Any use outside a research study
  • Anyone with cancer: thymosin β4, the parent protein, has been linked to tumour growth (see its entry)
  • Tested athletes: see the legal status below

Thymosin α1 side effects

Approved abroad · FDA listed it among nominated substances it says may present significant safety risks.

What FDA said

Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.

What human reports found

The controlled trials report reassuring safety, but with few specifics, and the combination cancer trials cannot separate its side effects from the other drugs'.

  • Sepsis (TESTS, 1,106 adults): no safety outcome differed from placebo
  • Chronic hepatitis B (98 patients): no significant side effects observed
  • COVID-19 pilot (49 patients): nine serious adverse events among treated patients, all judged unrelated
  • Flu-vaccine pilot in hemodialysis patients: no adverse event attributed to thymosin α1
  • Combination cancer regimens: side effects driven by the other drugs, with any-grade adverse events in 93.3% of the 2026 gastric-cancer trial
  • Sepsis subgroup: patients under 60 did worse on thymosin α1 than on placebo (hazard ratio 1.67), an unconfirmed signal

Who should not use it

  • Sepsis in adults under 60: the only large trial found a worse-outcome signal in this subgroup
  • Autoimmune disease: it is meant to boost immune responses, and no trial on this page tested it in autoimmune conditions. A reasoned caution, not a tested one
  • Hepatitis B or C: the trials compared it with interferon-era treatment or none, so they say nothing about adding it to current antivirals
  • Material from outside regulated supply: even a pharmacopoeia standard carried 23 measurable related impurities, and unregulated products are not tested at all
  • Pregnancy and breastfeeding: no data in our evidence set
Where this comes from

FDA's wording is quoted from its list of bulk drug substances that may present significant safety risks (content current as of 04/22/2026, read 2026-10-01 and re-checked November 18, 2026). Category 2 is FDA's interim-policy category for substances it says raise significant safety risks; the others were nominated for compounding and FDA's page gives its concerns about them. The human reports and the "who should not use it" lists are each peptide's own entry, where every report carries its source; a line that states a dose amount stays on the entry beside its source. See also the safety map for where safety data comes from across all peptides, and the interaction checker.